G1 Therapeutics (NASDAQ:GTHX) Releases Quarterly Earnings Results, Misses Estimates By $0.01 EPS

G1 Therapeutics (NASDAQ:GTHX) posted its earnings results on Wednesday. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.01), Zacks reports. G1 Therapeutics had a negative return on equity of 106.04% and a negative net margin of 58.13%. The company had revenue of $14.48 million for the quarter, compared to analyst estimates of $15.21 million. During the same quarter in the prior year, the business posted ($0.53) EPS.

G1 Therapeutics Price Performance

GTHX traded up $0.31 on Thursday, reaching $4.44. The stock had a trading volume of 727,333 shares, compared to its average volume of 1,254,980. The firm has a 50-day moving average of $3.85 and a 200-day moving average of $3.05. The company has a market capitalization of $232.26 million, a price-to-earnings ratio of -4.59 and a beta of 1.71. G1 Therapeutics has a fifty-two week low of $1.08 and a fifty-two week high of $5.00. The company has a current ratio of 3.87, a quick ratio of 3.45 and a debt-to-equity ratio of 1.46.

Insider Buying and Selling

In other G1 Therapeutics news, insider Rajesh Malik sold 28,600 shares of G1 Therapeutics stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $4.62, for a total transaction of $132,132.00. Following the transaction, the insider now directly owns 169,938 shares of the company’s stock, valued at approximately $785,113.56. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 8.23% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on GTHX. Needham & Company LLC reissued a “buy” rating and issued a $12.00 price target on shares of G1 Therapeutics in a report on Wednesday. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 price objective on shares of G1 Therapeutics in a report on Thursday. Finally, Wedbush reaffirmed an “outperform” rating and set a $5.00 price target (up previously from $4.00) on shares of G1 Therapeutics in a report on Wednesday, February 28th.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer in the United States. The company offers COSELA, which helps to decrease incidence of chemotherapy-induced myelosuppression in adult patients treated with a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer.